ACTRN12612000219886撤回2 期
A Randomised, Double-Blind, Active Placebo-Controlled Phase 2 Pilot Study of MDMA-Assisted Manualised Psychotherapy in Australian War Veterans with Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD).
Psychedelic Research in Science & Medicine Inc0 个研究点目标入组 14 人开始时间: 2012年2月21日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Meet DSM-IV criteria for chronic PTSD with a duration of at least six months.
- •2. Have a CAPS score of 50 or higher, indicating moderate to severe PTSD symptoms.
- •3. Have had at least one unsuccessful attempt at treatment for PTSD using drugs (SSRI, SNRI or MAOI) and/or psychotherapy; OR who discontinued treatment due to either: inability to tolerate psychotherapy for PTSD, or inability to tolerate psychopharmacology for PTSD due to treatment emergent side effects.
- •4. May have a concurrent affective disorder, excepting bipolar affective disorder 1.
- •5. Are war veterans.
- •6. If female and of childbearing potential, must have negative pregnancy test results, be willing to have pregnancy tests and must agree to use an effective form of birth control during throughout the treatment period.
- •7. Are proficient in speaking and reading English.
排除标准
- •1. Are pregnant or nursing, or of child bearing potential and not practising an effective method of birth control.
- •2. Have a personal or immediate family history of or current primary psychotic disorder, bipolar affective disorder type 1, or borderline personality disorder.
- •3. Are diagnosed with dissociative identity disorder or an eating disorder with active purging.
- •4.Have evidence or history of significant (controlled or uncontrolled) haematological, endocrine, cerebrovascular, cardiovascular, coronary, pulmonary, renal, gastrointestinal, immunocompromising, or neurological disease, including seizure disorder, or any other medical disorder judged by the investigator to significantly increase the risk of MDMA administration (participants with hypothyroidism who are on adequate and stable thyroid replacement will not be excluded).
- •5. Have hypertension using the standard criteria of the American Heart Association (values of 140/90 or higher assessed on three separate occasions) unless their hypertension has been successfully treated and is currently well-controlled on antihypertensive medicines. In this case participants with well-controlled hypertension may be enrolled if they pass additional screening to rule out underlying cardiovascular disease.
- •6. Have liver disease.
- •7. Have a history of Diabetes Type I or II.
- •8. Have a history of hyponatraemia or hyperthermia.
- •9. Weigh less than 48 kg.
- •10. Would present a serious suicide risk or who are likely to require hospitalisation during the course of the study.
- •11. Have used Ecstasy” (material represented as containing MDMA) more than five times in the past 3 years or at any time within 6 months of the MDMA session.
- •12. Require ongoing concomitant therapy with a psychiatric drug, including but not limited to SSRIs, SNRIs, or MAOIs.
- •13. Meet DSM-IV criteria for substance abuse or dependence for any substance save caffeine or nicotine in the past 60 days.
- •14. Have glaucoma, significant atherosclerosis or hyperthyroidism.
- •15. Have any current problem, which in the opinion of the investigator or medical
- •monitor, might interfere with participation in the study.
研究者
相似试验
已完成
不适用
Evaluation of safety/tolerability and pharmacokinetic/pharmacodynamics of YH12852 after oral administration in healthy subjectsKCT0000881Yuhan126
已完成
2 期
A dose-response study of scopolamine in major depressive disorderMental Health - DepressionMajor Depressive DisorderACTRN12619000569101The University of Auckland40
已完成
2 期
A randomised controlled study of an N-Methyl-D-Aspartate antagonist in major depressioMajor depressive disorderMental Health - DepressionDepressionACTRN12615000573550niversity of Auckland30
进行中（未招募）
1 期
A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant DepressioTreatment Resistant Major DepressionMedDRA version: 19.0Level: PTClassification code 10057840Term: Major depressionSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2013-004005-11-BEJanssen-Cilag International NV108
进行中（未招募）
不适用
A Randomized, Double-blind, Placebo Controlled Parallel-group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients with Early Stage Parkinson’s Disease - The Rembrandt studyParkinson's Disease Early StageEUCTR2005-006033-32-SESolvay Pharmaceuticals440